{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:40:53Z","timestamp":1792611653330,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ajog.2016.12.008","type":"journal-article","created":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T12:35:08Z","timestamp":1481718908000},"page":"443-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Unscheduled vaginal bleeding with progestin-only contraceptive use"],"prefix":"10.1016","volume":"216","author":[{"given":"Rachel E.","family":"Zigler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"McNicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2016.12.008_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.contraception.2007.06.008","article-title":"Contraceptive discontinuation attributed to method dissatisfaction in the United States","volume":"76","author":"Moreau","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib2","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/01.AOG.0000435452.86108.59","article-title":"Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use","volume":"122","author":"Grunloh","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2016.12.008_bib3","doi-asserted-by":"crossref","first-page":"662.e1","DOI":"10.1016\/j.ajog.2015.08.001","article-title":"Three-year continuation of reversible contraception","volume":"213","author":"Diedrich","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2016.12.008_bib4","series-title":"A\u00a0clinical guide for contraception","first-page":"109","article-title":"Oral contraception","author":"Speroff","year":"2011"},{"key":"10.1016\/j.ajog.2016.12.008_bib5","first-page":"1527","article-title":"Ovarian and endometrial function during hormonal contraception","volume":"16","year":"2011","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ajog.2016.12.008_bib6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1020072325818","article-title":"Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception","volume":"3","author":"Stanczyk","year":"2002","journal-title":"Rev Endocr Metab Disord"},{"issue":"6 Suppl 1","key":"10.1016\/j.ajog.2016.12.008_bib7","first-page":"S1","article-title":"Progestin-only oral contraception: a comprehensive review","volume":"50","author":"McCann","year":"1994","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib8","unstructured":"Faculty of Sexual and Reproductive Healthcare Clinical Guidance. Progestogen-only pills. 2008. Available at: http:\/\/www.fsrh.org\/documents\/progestogen-only-pills-jun-2009. Accessed November 10, 2016."},{"key":"10.1016\/j.ajog.2016.12.008_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0010-7824(88)90038-8","article-title":"Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception","volume":"38","author":"Belsey","year":"1988","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0010-7824(90)90077-9","article-title":"Clinical experience with the progestogen-only pill","volume":"42","author":"Broome","year":"1990","journal-title":"Contraception"},{"issue":"Suppl 2","key":"10.1016\/j.ajog.2016.12.008_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/humrep\/11.suppl_2.20","article-title":"Progestogen-only pills and\u00a0bleeding disturbances","volume":"11","author":"Kovacs","year":"1996","journal-title":"Hum Reprod"},{"issue":"5 Pt 2","key":"10.1016\/j.ajog.2016.12.008_bib12","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0002-9378(12)91813-X","article-title":"Long-acting injectable contraception with depot medroxyprogesterone acetate","volume":"170","author":"Kaunitz","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2016.12.008_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.contraception.2004.01.011","article-title":"Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera","volume":"70","author":"Jain","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib14","first-page":"339","article-title":"Plasma levels of medroxyprogesterone-acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotropin and prolactin in women during long term use of depo-MPA (Depo-Provera) as a contraceptive agent","volume":"99","author":"Jeppsson","year":"1982","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.ajog.2016.12.008_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.contraception.2009.02.008","article-title":"Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons","volume":"80","author":"Hubacher","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.contraception.2006.03.008","article-title":"Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous 104 mg","volume":"74","author":"Arias","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0010-7824(83)90040-9","article-title":"A\u00a0survey of different approaches to management of menstrual disturbances in women using injectable contraceptives","volume":"28","author":"Fraser","year":"1983","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/AOG.0000000000000690","article-title":"Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the US Food and Drug Administration\u2013approved duration","volume":"125","author":"McNicholas","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2016.12.008_bib19","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1093\/humrep\/dew222","article-title":"Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to the levonorgestrel-releasing subdermal implant","volume":"31","author":"Ali","year":"2016","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ajog.2016.12.008_bib20","series-title":"Contraceptive technology","first-page":"147","article-title":"Contraceptive implants","author":"Raymond","year":"2007"},{"key":"10.1016\/j.ajog.2016.12.008_bib21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0010-7824(98)00110-3","article-title":"Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon","volume":"58","author":"Wenzl","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib22","first-page":"CD003449","article-title":"Treatment of vaginal bleeding irregularities induced by progestin only contraceptives","author":"Abdel-Aleem","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"10.1016\/j.ajog.2016.12.008_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13625180801959931","article-title":"The effects of Implanon on menstrual bleeding patterns","volume":"13","author":"Mansour","year":"2008","journal-title":"Eur J Contracept Reprod Healthcare"},{"key":"10.1016\/j.ajog.2016.12.008_bib24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.contraception.2010.08.001","article-title":"The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users","volume":"83","author":"Mansour","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib25","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/GRF.0b013e318159c2f6","article-title":"The contraceptive implant","volume":"50","author":"Hohmann","year":"2007","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.ajog.2016.12.008_bib26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/AOG.0000000000000974","article-title":"Short-term treatment of bothersome bleeding for ENG implant users using a 14-day oral contraceptive pill regimen: a randomized controlled trial","volume":"126","author":"Guiahi","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2016.12.008_bib27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.contraception.2010.06.006","article-title":"Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability","volume":"82","author":"Lewis","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/humupd\/dmn003","article-title":"Intrauterine devices and intrauterine systems","volume":"14","year":"2008","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ajog.2016.12.008_bib29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.contraception.2016.02.024","article-title":"Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a\u00a07-year randomized comparative study with the TCu380A","volume":"93","author":"Rowe","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.contraception.2015.04.006","article-title":"Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system","volume":"92","author":"Eisenberg","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib31","unstructured":"Kyleena. Manufacturer package insert. Available at: http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Kyleena_PI.pdf. Accessed November 12, 2016."},{"key":"10.1016\/j.ajog.2016.12.008_bib32","unstructured":"Skyla. Manufacturer package insert. Available at: http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Skyla_PI.pdf. Accessed August 1, 2016."},{"key":"10.1016\/j.ajog.2016.12.008_bib33","unstructured":"Mirena. Manufacturer package insert. Available at: http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Mirena_PI.pdf. Accessed August 1, 2016."},{"key":"10.1016\/j.ajog.2016.12.008_bib34","unstructured":"Liletta. Manufacturer package insert. Available at: http:\/\/pi.actavis.com\/data_stream.asp?product_group=1960&p=pi&language=E. Accessed August 1, 2016."},{"key":"10.1016\/j.ajog.2016.12.008_bib35","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1093\/oxfordjournals.humrep.a136305","article-title":"The effect of local intrauterine levonorgestrel administration on endometrial thickness and uterine blood circulation","volume":"10","author":"Pakarinen","year":"1995","journal-title":"Hum Reprod"},{"issue":"Suppl 6","key":"10.1016\/j.ajog.2016.12.008_bib36","first-page":"593","article-title":"Endometrial effects of intrauterine levonorgestrel","volume":"75","author":"Guttinger","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib37","first-page":"CD000400","article-title":"Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding (Review)","author":"Lethaby","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2016.12.008_bib38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.contraception.2004.04.003","article-title":"Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users","volume":"70","author":"Tantiwattanakul","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib39","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.contraception.2005.09.013","article-title":"Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users","volume":"73","author":"Nathirojanakun","year":"2006","journal-title":"Contraception"},{"issue":"Suppl 3","key":"10.1016\/j.ajog.2016.12.008_bib40","first-page":"S64","article-title":"The effect of mefenamic acid on controlling irregular uterine bleeding second to Implanon use","volume":"87","author":"Phaliwong","year":"2004","journal-title":"J\u00a0Med Assoc Thai"},{"key":"10.1016\/j.ajog.2016.12.008_bib41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0010-7824(90)90094-C","article-title":"Clinical assessment of treatments for prolonged bleeding in users of Norplant implants","volume":"42","author":"Diaz","year":"1990","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.contraception.2008.04.003","article-title":"Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in LNG subcutaneous implant users","volume":"78","author":"Archer","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0010-7824(99)00059-1","article-title":"The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use","volume":"60","author":"Kaewrudee","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.contraception.2004.05.012","article-title":"Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding","volume":"70","author":"d\u2019Arcangues","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib45","first-page":"301","article-title":"Efficacy of celecoxib on controlling irregular uterine bleeding secondary to Jadelle use","volume":"92","author":"Buasang","year":"2009","journal-title":"J\u00a0Med Assoc Thai"},{"key":"10.1016\/j.ajog.2016.12.008_bib46","doi-asserted-by":"crossref","first-page":"129.e1","DOI":"10.1016\/j.ajog.2011.09.021","article-title":"Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial","volume":"206","author":"Madden","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 2","key":"10.1016\/j.ajog.2016.12.008_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/humrep\/11.suppl_2.1","volume":"11","author":"Said","year":"1996","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ajog.2016.12.008_bib48","first-page":"1","article-title":"Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial","volume":"15","author":"Hou","year":"2016","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.ajog.2016.12.008_bib49","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0002-9378(96)70326-5","article-title":"Hormonal treatment for bleeding irregularities in Norplant implant users","volume":"174","author":"Alvarez-Sanchez","year":"1996","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 2","key":"10.1016\/j.ajog.2016.12.008_bib50","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/humrep\/11.suppl_2.115","article-title":"The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users","volume":"11","author":"Boonkasemsanti","year":"1996","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ajog.2016.12.008_bib51","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.contraception.2012.01.003","article-title":"Doxycycline in the treatment of bleeding with DMPA: a double-blinded RCT","volume":"86","author":"Abdel-Aleem","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/humrep\/dei273","article-title":"A\u00a0pilot study to assess the effect of three short-term treatments on frequent and\/or prolonged bleeding compared to placebo in women using Implanon","volume":"21","author":"Weisberg","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ajog.2016.12.008_bib53","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/humrep\/dep081","article-title":"A\u00a0randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users","volume":"24","author":"Weisberg","year":"2009","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ajog.2016.12.008_bib54","first-page":"461","article-title":"The effect of tranexamic acid for treatment irregular uterine bleeding secondary to DMPA use","volume":"92","author":"Senthong","year":"2009","journal-title":"J\u00a0Med Assoc Thai"},{"key":"10.1016\/j.ajog.2016.12.008_bib55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.contraception.2005.09.012","article-title":"The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplant use","volume":"73","author":"Phupong","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib56","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/AOG.0b013e31828c65d8","article-title":"Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial","volume":"121","author":"Sordal","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2016.12.008_bib57","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0039-128X(03)00132-6","article-title":"Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate","volume":"68","author":"Jain","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.ajog.2016.12.008_bib58","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.contraception.2004.02.009","article-title":"Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users","volume":"70","author":"Massai","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib59","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.contraception.2016.10.001","article-title":"Tamoxifen for the treatment of breakthrough bleeding with the etonogestrel implant: a randomized controlled trial","volume":"95","author":"Simmons","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2016.12.008_bib60","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.contraception.2005.05.015","article-title":"Tamoxifen treatment of bleeding irregularities associated with Norplant use","volume":"72","author":"Abdel-Aleem","year":"2005","journal-title":"Contraception"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937816331763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937816331763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:13:35Z","timestamp":1757589215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937816331763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0002937816331763"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2016.12.008","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unscheduled vaginal bleeding with progestin-only contraceptive use","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2016.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}